Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2020—Personal Genome Diagnostics received the CE mark for the PGDx Elio Tissue Complete assay. The panel is a 507-gene test for somatic alterations that detects single nucleotide variants, small indels, amplifications, rearrangements, microsatellite instability, and tumor mutation burden.
January 2020—ALPCO announced that the FDA granted its Calprotectin Chemiluminescence ELISA 510(k) clearance. It is intended for in vitro diagnostic use as an aid in the diagnosis of inflammatory bowel disease, specifically Crohn’s disease and ulcerative colitis, and as an aid in the differentiation of IBD from irritable bowel syndrome, in conjunction with other clinical and laboratory findings.
January 2020—Genentech announced positive data from the phase three IMpower110 study evaluating Tecentriq (atezolizumab) as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced nonsquamous and squamous non-small cell lung cancer without ALK or EGFR mutations.
January 2020—Qiagen’s QuantiFeron-TB Gold Plus has been added to the diagnostic catalog of the Stop TB Partnership’s Global Drug Facility. The GDF provides quality-assured tuberculosis medicines, diagnostics, and laboratory supplies to the public sector.
January 2020—The FDA approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35 kg (approximately 77 lbs.) for HIV-1 pre-exposure prophylaxis to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. (Descovy is not indicated in individuals at risk of HIV-1 infection from receptive vaginal sex, the company reports, because the effectiveness in this population has not been evaluated.)
January 2020—ChromaCode has launched the HDPCR Multi-Drug Resistance (MDR) Panel, a highly multiplexed real-time PCR assay. The panel detects nine of the most common causes of Gram-negative multidrug resistance and toxigenic Clostridium difficile in a 96-well format. Key features of the panel, the company reports, include seamless integration onto common qPCR instrumentation, scalable throughput, and streamlined data analysis, management, and test customization with ChromaCode Cloud software. The MDR panel is for research use only.
January 2020—The FDA has approved Myriad Genetics’ MyChoice CDx for use as a companion diagnostic to identify women with advanced ovarian cancer who are candidates for Zejula (niraparib) in the late-line treatment setting. The FDA also approved the expanded use of Zejula (GlaxoSmithKline) for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency.
January 2020—Oxford Gene Technology has developed the CytoSure NGS panel for the detection of loss of heterozygosity, mosaicism, copy number variants, single nucleotide variants, and indels. The solution features up-to-date content for intellectual disability and developmental delay, the targeted NGS panel, and Interpret software.
January 2020—Veracyte and NanoString have entered into an agreement in which Veracyte has obtained exclusive worldwide rights to develop and commercialize diagnostic tests on NanoString’s nCounter Flex system.
January 2020—Microbiologics has launched rifampicin-resistant Mycobacterium tuberculosis positive and negative control panels for quality control of MTB-RIF molecular assays and test methods. Features of the controls include separate positive and negative control products, positive control representing five common mutations to the rpoB gene associated with rifampicin resistance (L511P, H526Y, S531L, D516V, S522L), room-temperature storage, and inactivated microorganism pellets for in vitro diagnostic use.
